By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare announced after the close of the market on Wednesday that it has completed the tender offer for all outstanding shares of common and preferred stock of Clarient.

GE Healthcare announced its plan to buy the Aliso Viejo, Calif.-based molecular diagnostics and imaging firm in October for $580 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.